Inhibitor of nuclear factor kappa-B kinase complex - Nuclear factor kappa-B signaling axis (IKK-NF-kappaB axis)

The Inhibitor of nuclear factor kappa-B kinase (IKK) complex - Nuclear factor kappa-B (NF-kappaB) signaling axis is a fundamental pathway regulating immune responses, inflammation, and cell survival [1]. The IKK complex, comprising IKKalpha, IKKbeta, and NEMO, acts as the primary integrator of upstream signals, phosphorylating IkappaB proteins to trigger their degradation [2]. This process allows NF-kappaB transcription factors to move into the nucleus and activate genes involved in cytokine production and anti-apoptotic pathways [3]. In many cancers and inflammatory diseases, this axis is constitutively active, driving disease progression and resistance to apoptosis [4]. Therapeutic interventions target various nodes of this axis, including IKK inhibition and proteasome-mediated IkappaB degradation blockade [5]. However, the broad physiological importance of NF-kappaB signaling presents significant challenges, as systemic inhibition can lead to severe immunosuppression and other off-target effects [6]. References: [1] PMC2851234; [2] UniProt O14920; [3] Nature Reviews Immunology 12, 689-701; [4] StatPearls NBK557444; [5] PubMed 24351987; [6] ScienceDirect IKK Complex.

Other names

IKK/NF-kappaB pathwayIKK complexNF-kappaB signaling pathwayIkappaB kinase complexNF-kappaB axis

Inhibition of the IKK complex prevents the phosphorylation and subsequent proteasomal degradation of IkappaB proteins, thereby sequestering NF-kappaB in the cytoplasm and preventing its transcriptional activity [1, 3]. Other therapeutic strategies include the use of proteasome inhibitors to prevent IkappaB degradation or agents that directly interfere with NF-kappaB DNA binding and nuclear translocation [5, 6].